Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 151

1.

Inter-Vendor Reproducibility of Myelin Water Imaging Using a 3D Gradient and Spin Echo Sequence.

Lee LE, Ljungberg E, Shin D, Figley CR, Vavasour IM, Rauscher A, Cohen-Adad J, Li DKB, Traboulsee AL, MacKay AL, Lee J, Kolind SH.

Front Neurosci. 2018 Nov 21;12:854. doi: 10.3389/fnins.2018.00854. eCollection 2018.

2.

Increased mean R2* in the deep gray matter of multiple sclerosis patients: Have we been measuring atrophy?

Hernández-Torres E, Wiggermann V, Machan L, Sadovnick AD, Li DKB, Traboulsee A, Hametner S, Rauscher A.

J Magn Reson Imaging. 2018 Dec 4. doi: 10.1002/jmri.26561. [Epub ahead of print]

PMID:
30511803
3.

Diffusely Abnormal White Matter, T2 Burden of Disease, and Brain Volume in Relapsing-Remitting Multiple Sclerosis.

Vertinsky AT, Li DKB, Vavasour IM, Miropolsky V, Zhao G, Zhao Y, Riddehough A, Moore GRW, Traboulsee A, Laule C.

J Neuroimaging. 2018 Oct 30. doi: 10.1111/jon.12574. [Epub ahead of print]

PMID:
30376195
4.

Goodpasture's Syndrome Following Alemtuzumab Therapy in Multiple Sclerosis.

Lapointe E, Moghaddam B, Barclay K, Traboulsee AL, Neufeld P.

Can J Neurol Sci. 2018 Nov;45(6):712-714. doi: 10.1017/cjn.2018.325. Epub 2018 Oct 2. No abstract available.

PMID:
30277178
5.

Safety and efficacy of venoplasty in MS: A randomized, double-blind, sham-controlled phase II trial.

Traboulsee AL, Machan L, Girard JM, Raymond J, Vosoughi R, Hardy BW, Emond F, Gariepy JL, Bone JN, Siskin G, Klass D, Isserow S, Illes J, Sadovnick AD, Li DK.

Neurology. 2018 Oct 30;91(18):e1660-e1668. doi: 10.1212/WNL.0000000000006423. Epub 2018 Sep 28.

6.

Education, and the balance between dynamic and stationary functional connectivity jointly support executive functions in relapsing-remitting multiple sclerosis.

Lin SJ, Vavasour I, Kosaka B, Li DKB, Traboulsee A, MacKay A, McKeown MJ.

Hum Brain Mapp. 2018 Dec;39(12):5039-5049. doi: 10.1002/hbm.24343. Epub 2018 Sep 21.

PMID:
30240533
7.

Nothing Ventured, Nothing Gained? Navigating Disease-Modifying Treatment in Multiple Sclerosis.

Burton JM, Traboulsee A.

Can J Neurol Sci. 2018 Sep;45(5):487-488. doi: 10.1017/cjn.2018.317. No abstract available.

PMID:
30234473
8.

Multicenter Measurements of T1 Relaxation and Diffusion Tensor Imaging: Intra and Intersite Reproducibility.

Vavasour IM, Meyers SM, Mädler B, Harris T, Fu E, Li DKB, Traboulsee A, MacKay AL, Laule C.

J Neuroimaging. 2018 Sep 19. doi: 10.1111/jon.12559. [Epub ahead of print]

PMID:
30230638
9.
10.

Gadolinium Deposition in Deep Brain Structures: Relationship with Dose and Ionization of Linear Gadolinium-Based Contrast Agents.

Kang H, Hii M, Le M, Tam R, Riddehough A, Traboulsee A, Kolind S, Freedman MS, Li DKB.

AJNR Am J Neuroradiol. 2018 Sep;39(9):1597-1603. doi: 10.3174/ajnr.A5751. Epub 2018 Aug 23.

PMID:
30139752
11.

Reflections on translation: Views of participants in a multisite Canadian CCSVI clinical trial.

Benjaminy S, Lo C, Illes J, Traboulsee A.

Neurol Clin Pract. 2018 Jun;8(3):232-239. doi: 10.1212/CPJ.0000000000000462. Review.

PMID:
30105163
12.

Common variation near IRF6 is associated with IFN-β-induced liver injury in multiple sclerosis.

Kowalec K, Wright GEB, Drögemöller BI, Aminkeng F, Bhavsar AP, Kingwell E, Yoshida EM, Traboulsee A, Marrie RA, Kremenchutzky M, Campbell TL, Duquette P, Chalasani N, Wadelius M, Hallberg P, Xia Z, De Jager PL, Denny JC, Davis MF, Ross CJD, Tremlett H, Carleton BC.

Nat Genet. 2018 Aug;50(8):1081-1085. doi: 10.1038/s41588-018-0168-y. Epub 2018 Jul 16.

PMID:
30013178
13.

Resilience, trust, and civic engagement in the post-CCSVI era.

Benjaminy S, Schepmyer A, Illes J, Traboulsee A.

BMC Health Serv Res. 2018 May 16;18(1):366. doi: 10.1186/s12913-018-3130-x.

14.

Predictive validity of NEDA in the 16- and 21-year follow-up from the pivotal trial of interferon beta-1b.

Goodin DS, Reder AT, Traboulsee AL, Li DK, Langdon D, Cutter G, Cook S, O'Donnell T, Kremenchutzky M, Oger J, Koelbach R, Pohl C, Wicklein EM; IFNB Multiple Sclerosis Study Group and the 16- and 21-Year LTF Investigators.

Mult Scler. 2018 May 1:1352458518773511. doi: 10.1177/1352458518773511. [Epub ahead of print]

PMID:
29761737
15.
16.

A 24-month advanced magnetic resonance imaging study of multiple sclerosis patients treated with alemtuzumab.

Vavasour IM, Tam R, Li DK, Laule C, Taylor C, Kolind SH, MacKay AL, Javed A, Traboulsee A.

Mult Scler. 2018 Apr 1:1352458518770085. doi: 10.1177/1352458518770085. [Epub ahead of print]

PMID:
29663845
17.

No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a.

Havrdová E, Arnold DL, Bar-Or A, Comi G, Hartung HP, Kappos L, Lublin F, Selmaj K, Traboulsee A, Belachew S, Bennett I, Buffels R, Garren H, Han J, Julian L, Napieralski J, Hauser SL, Giovannoni G.

Mult Scler J Exp Transl Clin. 2018 Mar 12;4(1):2055217318760642. doi: 10.1177/2055217318760642. eCollection 2018 Jan-Mar.

18.

What Have We Learned from Perfusion MRI in Multiple Sclerosis?

Lapointe E, Li DKB, Traboulsee AL, Rauscher A.

AJNR Am J Neuroradiol. 2018 Jun;39(6):994-1000. doi: 10.3174/ajnr.A5504. Epub 2018 Jan 4. Review.

PMID:
29301779
19.

Paraneoplastic Neuromyelitis Optica Spectrum Disorder: A single center cohort description with two cases of histological validation.

Beauchemin P, Iorio R, Traboulsee AL, Field T, Tinker AV, Carruthers RL.

Mult Scler Relat Disord. 2018 Feb;20:37-42. doi: 10.1016/j.msard.2017.12.012. Epub 2017 Dec 23.

PMID:
29291482
20.

Subcutaneous interferon β-1a three times weekly and the natural evolution of gadolinium-enhancing lesions into chronic black holes in relapsing and progressive multiple sclerosis: Analysis of PRISMS and SPECTRIMS trials.

Traboulsee A, Li D, Tam R, Zhao G, Riddehough A, Fang J, Dangond F, Kappos L; PRISMS and SPECTRIMS Working Groups.

Mult Scler J Exp Transl Clin. 2017 Dec 8;3(4):2055217317745340. doi: 10.1177/2055217317745340. eCollection 2017 Oct-Dec.

21.

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.

Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA.

Lancet Neurol. 2018 Feb;17(2):162-173. doi: 10.1016/S1474-4422(17)30470-2. Epub 2017 Dec 21. Review.

PMID:
29275977
22.

Deep learning of joint myelin and T1w MRI features in normal-appearing brain tissue to distinguish between multiple sclerosis patients and healthy controls.

Yoo Y, Tang LYW, Brosch T, Li DKB, Kolind S, Vavasour I, Rauscher A, MacKay AL, Traboulsee A, Tam RC.

Neuroimage Clin. 2017 Oct 14;17:169-178. doi: 10.1016/j.nicl.2017.10.015. eCollection 2018.

23.

Analysis of NOD-like receptor NLRP1 in multiple sclerosis families.

Bernales CQ, Encarnacion M, Criscuoli MG, Yee IM, Traboulsee AL, Sadovnick AD, Vilariño-Güell C.

Immunogenetics. 2018 Mar;70(3):205-207. doi: 10.1007/s00251-017-1034-2. Epub 2017 Oct 7.

PMID:
28988323
24.

Rapid myelin water imaging in human cervical spinal cord.

Ljungberg E, Vavasour I, Tam R, Yoo Y, Rauscher A, Li DKB, Traboulsee A, MacKay A, Kolind S.

Magn Reson Med. 2017 Oct;78(4):1482-1487. doi: 10.1002/mrm.26551. Epub 2016 Nov 9.

PMID:
28940333
25.

Characterization of brain tumours with spin-spin relaxation: pilot case study reveals unique T 2 distribution profiles of glioblastoma, oligodendroglioma and meningioma.

Laule C, Bjarnason TA, Vavasour IM, Traboulsee AL, Wayne Moore GR, Li DKB, MacKay AL.

J Neurol. 2017 Nov;264(11):2205-2214. doi: 10.1007/s00415-017-8609-6. Epub 2017 Sep 11.

PMID:
28894952
26.

Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.

Coles AJ, Cohen JA, Fox EJ, Giovannoni G, Hartung HP, Havrdova E, Schippling S, Selmaj KW, Traboulsee A, Compston DAS, Margolin DH, Thangavelu K, Chirieac MC, Jody D, Xenopoulos P, Hogan RJ, Panzara MA, Arnold DL; CARE-MS II and CAMMS03409 Investigators.

Neurology. 2017 Sep 12;89(11):1117-1126. doi: 10.1212/WNL.0000000000004354. Epub 2017 Aug 23.

27.

Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy.

Havrdova E, Arnold DL, Cohen JA, Hartung HP, Fox EJ, Giovannoni G, Schippling S, Selmaj KW, Traboulsee A, Compston DAS, Margolin DH, Thangavelu K, Rodriguez CE, Jody D, Hogan RJ, Xenopoulos P, Panzara MA, Coles AJ; CARE-MS I and CAMMS03409 Investigators.

Neurology. 2017 Sep 12;89(11):1107-1116. doi: 10.1212/WNL.0000000000004313. Epub 2017 Aug 23. Erratum in: Neurology. 2018 Apr 17;90(16):755.

28.

Global loss of myelin water over 5 years in multiple sclerosis normal-appearing white matter.

Vavasour IM, Huijskens SC, Li DK, Traboulsee AL, Mädler B, Kolind SH, Rauscher A, Moore GW, MacKay AL, Laule C.

Mult Scler. 2018 Oct;24(12):1557-1568. doi: 10.1177/1352458517723717. Epub 2017 Aug 7.

PMID:
28782447
29.

Cervical cord myelin water imaging shows degenerative changes over one year in multiple sclerosis but not neuromyelitis optica spectrum disorder.

Combes AJE, Matthews L, Lee JS, Li DKB, Carruthers R, Traboulsee AL, Barker GJ, Palace J, Kolind S.

Neuroimage Clin. 2017 Jun 16;16:17-22. doi: 10.1016/j.nicl.2017.06.019. eCollection 2017.

30.

Prehistoric enemies within: The contribution of human endogenous retroviruses to neurological diseases. Meeting report: "Second International Workshop on Human Endogenous Retroviruses and Disease", Washington DC, March 13th and 14th 2017.

Kremer D, Glanzman R, Traboulsee A, Nath A, Groc L, Horwitz M, Göttle P, Perron H, Gold J, Hartung HP, Küry P.

Mult Scler Relat Disord. 2017 Jul;15:18-23. doi: 10.1016/j.msard.2017.05.001. Epub 2017 May 1.

PMID:
28641767
31.

Prognostic factors for long-term outcomes in relapsing-remitting multiple sclerosis.

Traboulsee AL, Cornelisseª P, Sandberg-Wollheim M, Uitdehaag BM, Kappos L, Jongen PJ, Constantinescu CS, di Cantogno EV, Li DK.

Mult Scler J Exp Transl Clin. 2016 Sep 6;2:2055217316666406. doi: 10.1177/2055217316666406. eCollection 2016 Jan-Dec.

32.

Application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: a case-control study protocol for dimethyl fumarate-induced lymphopenia.

Kowalec K, Kingwell E, Carruthers R, Marrie RA, Bernatsky S, Traboulsee A, Ross CJD, Carleton B, Tremlett H.

BMJ Open. 2017 Jun 2;7(5):e016276. doi: 10.1136/bmjopen-2017-016276.

33.

Trial of Minocycline in a Clinically Isolated Syndrome of Multiple Sclerosis.

Metz LM, Li DKB, Traboulsee AL, Duquette P, Eliasziw M, Cerchiaro G, Greenfield J, Riddehough A, Yeung M, Kremenchutzky M, Vorobeychik G, Freedman MS, Bhan V, Blevins G, Marriott JJ, Grand'Maison F, Lee L, Thibault M, Hill MD, Yong VW; Minocycline in MS Study Team.

N Engl J Med. 2017 Jun 1;376(22):2122-2133. doi: 10.1056/NEJMoa1608889.

PMID:
28564557
34.

Genetic modifiers of multiple sclerosis progression, severity and onset.

Sadovnick AD, Traboulsee AL, Zhao Y, Bernales CQ, Encarnacion M, Ross JP, Yee IM, Criscuoli MG, Vilariño-Güell C.

Clin Immunol. 2017 Jul;180:100-105. doi: 10.1016/j.clim.2017.05.009. Epub 2017 May 10.

PMID:
28501589
35.

Evaluating the safety of β-interferons in MS: A series of nested case-control studies.

de Jong HJI, Kingwell E, Shirani A, Cohen Tervaert JW, Hupperts R, Zhao Y, Zhu F, Evans C, van der Kop ML, Traboulsee A, Gustafson P, Petkau J, Marrie RA, Tremlett H; British Columbia Multiple Sclerosis Clinic Neurologists.

Neurology. 2017 Jun 13;88(24):2310-2320. doi: 10.1212/WNL.0000000000004037. Epub 2017 May 12.

36.

Susceptibility-sensitive MRI of multiple sclerosis lesions and the impact of normal-appearing white matter changes.

Wiggermann V, Hametner S, Hernández-Torres E, Kames C, Endmayr V, Kasprian G, Höftberger R, Li DKB, Traboulsee A, Rauscher A.

NMR Biomed. 2017 Aug;30(8). doi: 10.1002/nbm.3727. Epub 2017 May 4.

PMID:
28470768
37.

Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: A systematic review.

Merkel B, Butzkueven H, Traboulsee AL, Havrdova E, Kalincik T.

Autoimmun Rev. 2017 Jun;16(6):658-665. doi: 10.1016/j.autrev.2017.04.010. Epub 2017 Apr 17. Review.

38.

Common genetic etiology between "multiple sclerosis-like" single-gene disorders and familial multiple sclerosis.

Traboulsee AL, Sadovnick AD, Encarnacion M, Bernales CQ, Yee IM, Criscuoli MG, Vilariño-Güell C.

Hum Genet. 2017 Jun;136(6):705-714. doi: 10.1007/s00439-017-1784-9. Epub 2017 Mar 23.

PMID:
28337550
39.

Purinergic receptors P2RX4 and P2RX7 in familial multiple sclerosis.

Sadovnick AD, Gu BJ, Traboulsee AL, Bernales CQ, Encarnacion M, Yee IM, Criscuoli MG, Huang X, Ou A, Milligan CJ, Petrou S, Wiley JS, Vilariño-Güell C.

Hum Mutat. 2017 Jun;38(6):736-744. doi: 10.1002/humu.23218. Epub 2017 Apr 13.

40.

Patient-Reported Benefits of Extracranial Venous Therapy: British Columbia CCSVI Registry.

Sadovnick AD, Yee IM, Attwell-Pope K, Keyes G, Kipp L, Traboulsee AL.

Can J Neurol Sci. 2017 May;44(3):246-254. doi: 10.1017/cjn.2017.27. Epub 2017 Mar 8.

PMID:
28270250
41.

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.

Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators.

N Engl J Med. 2017 Jan 19;376(3):209-220. doi: 10.1056/NEJMoa1606468. Epub 2016 Dec 21.

PMID:
28002688
42.

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.

Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L; OPERA I and OPERA II Clinical Investigators.

N Engl J Med. 2017 Jan 19;376(3):221-234. doi: 10.1056/NEJMoa1601277. Epub 2016 Dec 21.

PMID:
28002679
43.

Cognitive Performance in Subjects With Multiple Sclerosis Is Robustly Influenced by Gender in Canonical-Correlation Analysis.

Lin SJ, Lam J, Beveridge S, Vavasour I, Traboulsee A, Li DKB, MacKay A, McKeown M, Kosaka B.

J Neuropsychiatry Clin Neurosci. 2017 Spring;29(2):119-127. doi: 10.1176/appi.neuropsych.16040083. Epub 2016 Nov 30.

PMID:
27899053
44.

Prevalence of Extracranial Venous Narrowing on Magnetic Resonance Venography Is Similar in People With Multiple Sclerosis, Their Siblings, and Unrelated Healthy Controls: A Blinded, Case-Control Study.

Martin N, Traboulsee AL, Machan L, Klass D, Ellchuk T, Zhao Y, Knox KB, Kopriva D, Lala S, Nickel D, Otani R, Perera WR, Rauscher A, Sadovnick AD, Szkup P, Li DK.

Can Assoc Radiol J. 2017 May;68(2):202-209. doi: 10.1016/j.carj.2016.07.002. Epub 2016 Nov 22.

PMID:
27887935
45.

Nuclear Receptor NR1H3 in Familial Multiple Sclerosis.

Wang Z, Sadovnick AD, Traboulsee AL, Ross JP, Bernales CQ, Encarnacion M, Yee IM, de Lemos M, Greenwood T, Lee JD, Wright G, Ross CJ, Zhang S, Song W, Vilariño-Güell C.

Neuron. 2016 Oct 19;92(2):555. doi: 10.1016/j.neuron.2016.09.028. No abstract available.

46.

Case-Control Studies Are Not Familial Studies.

Wang Z, Sadovnick AD, Traboulsee AL, Ross JP, Bernales CQ, Encarnacion M, Yee IM, de Lemos M, Greenwood T, Lee JD, Wright G, Ross CJ, Zhang S, Song W, Vilariño-Güell C.

Neuron. 2016 Oct 19;92(2):339-341. doi: 10.1016/j.neuron.2016.09.053.

47.

Editorial Note to:Nuclear Receptor NR1H3 in Familial Multiple Sclerosis.

Wang Z, Sadovnick AD, Traboulsee AL, Ross JP, Bernales CQ, Encarnacion M, Yee IM, de Lemos M, Greenwood T, Lee JD, Wright G, Ross CJ, Zhang S, Song W, Vilariño-Güell C.

Neuron. 2016 Oct 19;92(2):331-332. doi: 10.1016/j.neuron.2016.10.008. No abstract available.

48.

Brain health: time matters in multiple sclerosis.

Giovannoni G, Butzkueven H, Dhib-Jalbut S, Hobart J, Kobelt G, Pepper G, Sormani MP, Thalheim C, Traboulsee A, Vollmer T.

Mult Scler Relat Disord. 2016 Sep;9 Suppl 1:S5-S48. doi: 10.1016/j.msard.2016.07.003. Epub 2016 Jul 7. Review.

49.

Addressing Concerns Regarding the Use of Gadolinium in a Standardized MRI Protocol for the Diagnosis and Follow-Up of Multiple Sclerosis.

Traboulsee A, Li D.

AJNR Am J Neuroradiol. 2016 Dec;37(12):E82-E83. Epub 2016 Sep 1. No abstract available.

50.

Supplemental Content

Loading ...
Support Center